BRAF and melanoma: The NeoCombi phase II trial (NCT 01972347) evaluated the safety and efficacy of neoadjuvant dabrafenib plus trametinib in 35 BRAF-mutant resectable stage IIIB-C melanoma patients; these patients received a treatment based on 12 weeks of neoadjuvant therapy, followed by 40 weeks of adjuvant therapy [76].